Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.69 |
| ▸ | MEN1 | O00255 | 2/20 | 0.69 |
| ▸ | RAB9A | P51151 | 2/20 | 0.69 |
| ▸ | NPC1 | O15118 | 1/20 | 0.69 |
| ▸ | FLT3 | P36888 | 8/20 | 0.60 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | RAF1 | P04049 | 5/20 | 0.57 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.57 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.57 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4037899 | 0.84 | ALDH1A1 (0.70) | KMT2AMEN1RAB9ANPC1MAPT | |
| SCHEMBL4875323 | 0.83 | MEN1 (0.62) | KMT2AMEN1RAB9ANPC1FLT3 | |
| SCHEMBL1012716 | 0.83 | RAB9A (0.76) | KMT2AMEN1RAB9ANPC1FLT3 | |
| SCHEMBL14014125 | 0.83 | KMT2A (0.76) | KMT2AMEN1RAB9ANPC1FLT3 | |
| SCHEMBL2518089 | 0.82 | MEN1 (1.00) | KMT2AMEN1RAB9ANPC1FLT3 | |
| SCHEMBL4716313 | 0.82 | KMT2A (0.60) | KMT2AMEN1RAB9ANPC1FLT3 | |
| SCHEMBL4717254 | 0.82 | MEN1 (0.60) | KMT2AMEN1RAB9ANPC1FLT3 | |
| SCHEMBL4716331 | 0.82 | MEN1 (0.60) | KMT2AMEN1RAB9ANPC1FLT3 | |
| SCHEMBL1010628 | 0.81 | KMT2A (0.74) | KMT2AMEN1RAB9ANPC1FLT3 | |
| SCHEMBL13234449 | 0.81 | KMT2A (0.74) | KMT2AMEN1RAB9ANPC1FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1737462-B1 | PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | ASTRAZENECA AB (SE) | 2008-07-30 | — | — | EP | disclosed |
| US-20080153838-A1 | Compounds Having Tie2 (Tek) Activity | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | US | disclosed |
| US-20080153838-A1 | Compounds Having Tie2 (Tek) Activity | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | US | disclosed |
| US-20080153838-A1 | Compounds Having Tie2 (Tek) Activity | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | US | disclosed |
| US-20080027076-A1 | Pyrimidines With Tie2 (Tek) Activity | ASTRAZENECA AB (SE) | 2008-01-31 | — | — | US | disclosed |
| EP-1848715-A1 | COMPOUNDS HAVING TIE2 (TEK) INHIBITORY ACTIVITY | AstraZeneca AB (SE) | 2007-10-31 | — | — | EP | disclosed |
| EP-1737462-A1 | PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | AstraZeneca AB (SE) | 2007-01-03 | — | — | EP | disclosed |
| WO-2006082404-A1 | COMPOUNDS HAVING TIE2 (TEK) INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2006-08-10 | — | — | WO | disclosed |
| WO-2005060969-A1 | PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | ASTRAZENECA AB (SE) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153838-A1 | Compounds Having Tie2 (Tek) Activity | TEK, TIE1, KDR | KMT2A 163/4885MEN1 187/4885RAB9A 4395/4885 |
| US-20080027076-A1 | Pyrimidines With Tie2 (Tek) Activity | TIE1, TEK, TEKT1 | KMT2A 162/4885MEN1 1106/4885RAB9A 4665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.